semaglutide canada patent Generic versions of weight-loss drugs should arrive on Canadian pharmacy shelves this summer Generic Ozempic coming to Canada:

VK2735 VK2735 is an advanced dual GIP/GLP-1 receptor agonist with promising efficacy and the potential to become a major competitor in the injectable obesity market

Not applicable

IntroductionThe surge in prescribing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for diabetes and weight management highlights a pressing need to c...

Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal care after resolution of Covid-19 symptoms

Houston, TX

The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition, according to an agency press release.Weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014.